Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 positive||colorectal cancer||predicted - sensitive||Trastuzumab deruxtecan||Phase I||Actionable||In a Phase I trial, treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) resulted in an objective response rate of 25% (3/12) and disease control rate of 83.3% (10/12) in evaluable patients with Erbbe (Her2)-expressing colorectal cancer (Annals of Oncology (2018) 29 (suppl_8): viii150-viii204; NCT02564900).||detail...|
|PubMed Id||Reference Title||Details|
|Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer||Full reference...|